CBD-Based Drug Combination Therapy May Benefit Rheumatoid Arthritis

Incannex, an Australian pharmaceutical company, announced the first dosing in a phase 2 study of IHL-675A, the company’s proprietary and novel combination drug candidate composed of hydroxychloroquine sulphate (HCQ) and cannabidiol (CBD), for the treatment of inflammatory diseases, including rheumatoid arthritis (RA). In earlier studies, Incannex demonstrated that the IHL-675A components, HCQ and CBD, act synergistically to inhibit production of inflammatory cytokines and reduce disease severity.

DocWire News spoke with Dr. Mark Bleackley, chief scientific officer, Incannex Healthcare Inc., who discussed this promising therapy combination, which has the potential to positively impact individuals living with RA.